• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高浓度或联合反义寡核苷酸治疗脊髓性肌萎缩症患者成纤维细胞中剪接异常。

High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed Splicing in Patient Fibroblasts.

机构信息

Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Hyogo, Japan.

Department of Biochemistry, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Jalan Farmako, Yogyakarta 55281, Indonesia.

出版信息

Genes (Basel). 2022 Apr 13;13(4):685. doi: 10.3390/genes13040685.

DOI:10.3390/genes13040685
PMID:35456491
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9027857/
Abstract

Spinal muscular atrophy (SMA) is caused by deletion. The encodes the same protein as does, but it has a splicing defect of exon 7. Some antisense oligonucleotides (ASOs) have been proven to correct this defect. One of these, nusinersen, is effective in SMA-affected infants, but not as much so in advanced-stage patients. Furthermore, the current regimen may exhibit a ceiling effect. To overcome these problems, high-dose ASOs or combined ASOs have been explored. Here, using SMA fibroblasts, we examined the effects of high-concentration ASOs and of combining two ASOs. Three ASOs were examined: one targeting intronic splicing suppressor site N1 (ISS-N1) in intron 7, and two others targeting the 3' splice site and 5' region of exon 8. In our experiments on all ASO types, a low or intermediate concentration (50 or 100 nM) showed better splicing efficiency than a high concentration (200 nM). In addition, a high concentration of each ASO created a cryptic exon in exon 6. When a mixture of two different ASOs (100 nM each) was added to the cells, the cryptic exon was included in the mRNA. In conclusion, ASOs at a high concentration or used in combination may show less splicing correction and cryptic exon creation.

摘要

脊髓性肌萎缩症(SMA)是由缺失引起的。该基因编码与基因相同的蛋白质,但它在外显子 7 处存在剪接缺陷。一些反义寡核苷酸(ASO)已被证明可以纠正这种缺陷。其中一种名为 nusinersen 的药物在受影响的婴儿 SMA 中有效,但在晚期患者中效果不那么明显。此外,目前的治疗方案可能存在上限效应。为了克服这些问题,已经探索了高剂量 ASO 或联合 ASO。在这里,我们使用 SMA 成纤维细胞研究了高浓度 ASO 和联合两种 ASO 的效果。我们检查了三种 ASO:一种针对内含子 7 中的内含子剪接抑制物位点 N1(ISS-N1),另外两种针对 3'剪接位点和 5'外显子 8 区域。在我们对所有 ASO 类型的实验中,低浓度或中浓度(50 或 100 nM)比高浓度(200 nM)显示出更好的剪接效率。此外,每种 ASO 的高浓度都会在外显子 6 中产生一个隐蔽外显子。当向细胞中添加两种不同 ASO(每种 100 nM)的混合物时,隐蔽外显子会包含在 mRNA 中。总之,高浓度的 ASO 或联合使用可能会显示出较少的剪接纠正和隐蔽外显子的产生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/52d86d23b04a/genes-13-00685-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/8df390baba9b/genes-13-00685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/14f44679246e/genes-13-00685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/4d33cf3e589c/genes-13-00685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/52d86d23b04a/genes-13-00685-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/8df390baba9b/genes-13-00685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/14f44679246e/genes-13-00685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/4d33cf3e589c/genes-13-00685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3afc/9027857/52d86d23b04a/genes-13-00685-g004.jpg

相似文献

1
High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed Splicing in Patient Fibroblasts.高浓度或联合反义寡核苷酸治疗脊髓性肌萎缩症患者成纤维细胞中剪接异常。
Genes (Basel). 2022 Apr 13;13(4):685. doi: 10.3390/genes13040685.
2
Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.组蛋白去乙酰化酶抑制剂 LBH589 与剪接开关反义寡核苷酸联合治疗可增强脊髓性肌萎缩症细胞中 SMN2 的剪接和 SMN 的表达。
J Neurochem. 2020 Apr;153(2):264-275. doi: 10.1111/jnc.14935. Epub 2020 Jan 8.
3
Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264.脊髓性肌萎缩症的联合治疗:一篇关于“组蛋白去乙酰化酶抑制剂 LBH589 和剪接转换反义寡核苷酸联合治疗增强脊髓性肌萎缩症细胞中 SMN2 剪接和 SMN 表达”的评论,发表于第 264 页。
J Neurochem. 2020 Apr;153(2):146-149. doi: 10.1111/jnc.14974. Epub 2020 Feb 14.
4
Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.脊髓性肌萎缩症基因的剪接调控机制。
Adv Neurobiol. 2018;20:31-61. doi: 10.1007/978-3-319-89689-2_2.
5
A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy.一种掩盖独特内含子基序的短反义寡核苷酸可防止脊髓性肌萎缩症关键外显子的跳跃。
RNA Biol. 2009 Jul-Aug;6(3):341-50. doi: 10.4161/rna.6.3.8723. Epub 2009 Jul 14.
6
Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of in SMA Type I Fibroblasts.反义寡核苷酸诱导 hnRNPA1b 异构体影响 SMA 型 I 成纤维细胞的前体 mRNA 剪接。
Int J Mol Sci. 2022 Apr 1;23(7):3937. doi: 10.3390/ijms23073937.
7
High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome.高浓度靶向 ISS-N1 的反义寡核苷酸导致转录组的大规模紊乱。
Int J Mol Sci. 2021 Aug 4;22(16):8378. doi: 10.3390/ijms22168378.
8
Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.全身和局部吗啡啉联合治疗对脊髓性肌萎缩症Δ7小鼠模型表型的影响。
Clin Ther. 2014 Mar 1;36(3):340-56.e5. doi: 10.1016/j.clinthera.2014.02.004.
9
Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.用于治疗脊髓性肌萎缩症的反义靶点的作用机制原理
Future Med Chem. 2015;7(13):1793-808. doi: 10.4155/fmc.15.101. Epub 2015 Sep 18.
10
Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.高温增加全长 SMN 剪接:SMA 剪接增强治疗的希望。
Hum Genet. 2022 Feb;141(2):239-256. doi: 10.1007/s00439-021-02408-7. Epub 2022 Jan 28.

引用本文的文献

1
Treatability of the KMT2-Associated Neurodevelopmental Disorders Using Antisense Oligonucleotide-Based Treatments.使用基于反义寡核苷酸的疗法治疗与KMT2相关的神经发育障碍
Hum Mutat. 2024 May 29;2024:9933129. doi: 10.1155/2024/9933129. eCollection 2024.
2
Patient-specific responses to splice-modifying treatments in spinal muscular atrophy fibroblasts.脊髓性肌萎缩症成纤维细胞对剪接修饰治疗的个体特异性反应。
Mol Ther Methods Clin Dev. 2024 Nov 13;32(4):101379. doi: 10.1016/j.omtm.2024.101379. eCollection 2024 Dec 12.
3
Natural antisense transcripts as drug targets.

本文引用的文献

1
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis.2 型和 3 型 SMA 患者接受 nusinersen 治疗后的运动功能:批判性评价和荟萃分析。
Orphanet J Rare Dis. 2021 Oct 13;16(1):430. doi: 10.1186/s13023-021-02065-z.
2
High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome.高浓度靶向 ISS-N1 的反义寡核苷酸导致转录组的大规模紊乱。
Int J Mol Sci. 2021 Aug 4;22(16):8378. doi: 10.3390/ijms22168378.
3
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
作为药物靶点的天然反义转录本。
Front Mol Biosci. 2022 Sep 27;9:978375. doi: 10.3389/fmolb.2022.978375. eCollection 2022.
Risdiplam 治疗 1 型脊髓性肌萎缩症婴儿与历史对照。
N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047.
4
Spinal Muscular Atrophy.脊髓性肌萎缩症。
Semin Pediatr Neurol. 2021 Apr;37:100878. doi: 10.1016/j.spen.2021.100878. Epub 2021 Feb 11.
5
Risdiplam in Type 1 Spinal Muscular Atrophy.利司扑兰治疗 1 型脊髓性肌萎缩症。
N Engl J Med. 2021 Mar 11;384(10):915-923. doi: 10.1056/NEJMoa2009965. Epub 2021 Feb 24.
6
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.依地膦酸治疗神经母细胞瘤骨转移的安全性和疗效观察
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1166-1174. doi: 10.1136/jnnp-2020-323822. Epub 2020 Sep 11.
7
Combination molecular therapies for type 1 spinal muscular atrophy.1 型脊髓性肌萎缩症的联合分子治疗。
Muscle Nerve. 2020 Oct;62(4):550-554. doi: 10.1002/mus.27034. Epub 2020 Aug 10.
8
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care.脊髓性肌萎缩症治疗进展——新表型、新挑战、新护理意义。
J Neuromuscul Dis. 2020;7(1):1-13. doi: 10.3233/JND-190424.
9
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.在脊髓性肌萎缩症的前症状期对婴儿期开始用 nusinersen:2 期 NURTURE 研究的中期疗效和安全性结果。
Neuromuscul Disord. 2019 Nov;29(11):842-856. doi: 10.1016/j.nmd.2019.09.007. Epub 2019 Sep 12.
10
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).利司扑兰,一种运动神经元存活基因 2(SMN2)剪接修饰剂的发现,用于治疗脊髓性肌萎缩症(SMA)。
J Med Chem. 2018 Aug 9;61(15):6501-6517. doi: 10.1021/acs.jmedchem.8b00741. Epub 2018 Jul 25.